1-8 of 8
Keiji Nogami, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a

Midori Shima, MD, Sayaka Nagami, BSc, Koichiro Yoneyama, MSc, Akira Nomura, MSc, Yoshiyuki Ogawa, MD PhD, Kagehiro Amano, MD PhD, Keiji Nogami, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-136488
Published: 2020
Journal Articles

Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study)

Midori Shima, MD PhD, Keiji Nogami, MDPhD, Sayaka Nagami, BSc, Seitaro Yoshida, PhD, Koichiro Yoneyama, MSc, Akira Ishiguro, MD PhD, Takashi Suzuki, MD PhD, Masashi Taki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1186.
https://doi.org/10.1182/blood-2018-99-115792
Published: 2018
Journal Articles

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Beatrice Nolan, Johnny Mahlangu, Guy Young, Barbara A Konkle, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Johannes Oldenburg, MD PhD, Keiji Nogami, MDPhD, Nikola Tripkovic, Huixing Yuan, Dan Rudin
Journal: Blood
Blood (2018) 132 (Supplement 1): 1192.
https://doi.org/10.1182/blood-2018-99-118586
Published: 2018
Journal Articles

A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation

Yuto Nakajima, MD, Koji Yada, MD PhD, Keiji Nogami, MDPhD, Midori Shima, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1162.
https://doi.org/10.1182/blood-2018-99-115645
Published: 2018
Journal Articles

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Kenichi Ogiwara, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Mariko Noguchi-Sasaki, PhD, Tetsuhiro Soeda, PhD, Naoki Matsumoto, PhD, Michinori Hirata, PhD, Midori Shima, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1200.
https://doi.org/10.1182/blood-2018-99-118504
Published: 2018
Journal Articles

Contribution of Factor VIII A3 Domain Residues 1793-1795 to a Factor IXa-Interactive Site

Masahiro Takeyama, Keiji Nogami, MDPhD, Kana Sasai, Midori Shima, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1173.
https://doi.org/10.1182/blood-2018-99-113260
Published: 2018
Journal Articles

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

Koji Yada, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Takehisa Kitazawa, DVM, Midori Shima, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3658.
https://doi.org/10.1182/blood.V130.Suppl_1.3658.3658
Published: 2017
Journal Articles

A Factor VIII with Site-Specific Pegylation Attenuates the Binding with Inhibitors Results in the Retention of Hemostatic Effect

Koji Yada, MDPhD, Keiji Nogami, MDPhD, Chandra Patel, Derek Sim, Katalin Kauser, MD PhD, Midori Shima, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1076.
https://doi.org/10.1182/blood.V126.23.1076.1076
Published: 2015